Worst performer unfortunately didn't perform badly enough for my plans. IQE:IQE dropped 32% of cost price in my ISA and 16% of cost price in my SIPP, but I needed a bigger drop to buy my bargain shares on results day. All the drop has done is wipe out a huge amount of value and allow the hedge funds to close more of their shorts without affecting the share price.
The next two worst performers are the shares I bought when IQE:IQE didn't tank as much as I hoped. MTFB:Motif Bio dropped 15% and has gone from profit ever since I bought it to an 8% loss. VRS:Versarien was clobbered by 13% and is now only 2% up from when I bought them, but at least still in the black.
CAML:Central Asia Metals was Share of the Week last week, so no surprise it tanked 11% this week.
N4P:N4 Pharma was my other new purchase this week and that's already dropped 10%.
TND:Tandem Group fell 7% despite there being no trades that day, and WRES:W Resources is drifting south again on no news, also falling 7%
OPTI:Optibiotix only dropped 5% but the 3p fall contributed to £1,800 of the week's losses.
AMYT:Amryt Pharma is also falling relentlessly so I'm glad I sold 80% of my holding a while back. It dropped another 5% this week and is now making a 6% loss.
There were very few glimmers of hope this week, with one of the lowest ever increases for a Share of the Week.
LION:Lionsgold was a contender climbing 4%, RED:RedT Energy beat it by a percent climbing 5%, and Share of the Week goes to TLOU:Tlou Energy which also climbed 5% but beats RED:RedT Energy because I have more invested.
One of the biggest ever dips in value exacerbated by the big jump in cost as profits were re-invested. That's a very, very wide gap!
The ISA and share portfolios looks like this
| Weekly Change | |||
| Cash | £10.36 | -£2,198.04 | |
| Portfolio cost | £50,109.65 | +£2,783.60 | |
| Portfolio sell value (bid price - commission) | £42.293.52 | (-15.6%) | -£2,880.58 |
| Potential profits | £2,103.79 | -£1,484.46 | |
| Yr 3 Dividends | £44.15 | +£0 | |
| Yr 3 Profit from sales | £6,246.78 | +£581.92 | |
| Yr 3 Average monthly cash profit | £822.63 | (19.7%) | +£53.09 |
| Total Dividends | £1,223.20 | +£0 | |
| Total Profit from sales | £12,959.28 | +£581.92 | |
| Average monthly cash profit | £444.43 | (10.6%) | +£15.27 |
| (Sold stocks profit + Dividends - Fees / Months) |
All the spare cash was re-invested along with the proceeds of my final IQE:IQE top-slice, resulting in portfolio cost going above £50,000 and increasing by £2,783. Unfortunately, the value dropped by more than that and drops in potential profits made up half the loss, falling £1,484.
The good news is that the IQE:IQE sale increased banked profits by £581 and took my long-term average up by £15 a month and I stay over my 10% of portfolio cost target comfortably despite the portfolio cost going up so much.
I don't like to dwell on the graph...
Here's the SIPP after week 121
| Weekly Change | |||
| Cash | £30.10 | -£233.48 | |
| Portfolio cost | £27,016.24 | +£726.17 | |
| Portfolio sell value (bid price - commission) | £26,965.29 | (0.2%) | -£2,178.87 |
| Potential profits | £3,383.41 | -£1,165.29 | |
| Yr 3 Dividends | £0 | +£0 | |
| Yr 3 Profit from sales | £1,023.84 | +£485.19 | |
| Yr 3 Average monthly cash profit | £250.44 | (11.1%) | +£115.75 |
| Total Dividends | £916.10 | +£0 | |
| Total Profit from sales | £9,949.03 | +£485.19 | |
| Average monthly cash profit | £382.34 | (17%) | +£14.34 |
| (Sold stocks profit + Dividends - Fees / Months) |
The cash got re-invested along with the proceeds of the CAML:Central Asia Metals top-slice, and that went towards my first investment in N4P:N4 Pharma which it appears was badly timed. Portfolio value was savaged by £2,178 just over half of which was reduced profits of £1,165 but £484 of that was down to the sale. Average monthly performance has been enhanced, now running at a comfortable 17% of the enlarged portfolio cost.
Amazingly it just about stays in profit. Will the lines cross or bounce next week?
The trading account is a more welcome sight this week
| Weekly Change | |||
| Cash | £0.03 | +£0 | |
| Portfolio cost | £345.65 | +£0 | |
| Portfolio sell value (bid price - commission) | £176.52 | (-48.9%) | +£14.78 |
| Potential profits | £0 | +£0 | |
| Year 2 Dividends | £0 | +£0 | |
| Year 2 Profit | -£218.50 | +£0 | |
| Yr 2 Average monthly cash profit | -£27.05 | (-93.9%) | +£0.80 |
| Dividends | £1.15 | +£0 | |
| Profit from sales | -£241.35 | +£0 | |
| Average monthly cash profit | -£11.96 | (-41.5%) | +£0.14 |
| (Sold stocks profit + Dividends - Fees / Months) |
Last week's losses were gained back, but it's a long way from profit.
One day I hope this graph does something reasonably spectacular
I've done so many trades over the last few weeks that I'm planning for a more quiet time now. CAML:Central Asia Metals and IQE:IQE are now under the 10% portfolio cost limit and I've increased the number of shares with more than £3,000 investments, which now comprises of OPTI:Optibiotix, IQE:IQE, CAML:Central Asia Metals, JLP:Jubilee Metals, MTFB:Motif Bio and VRS:Versarien.
It's time to sit back for a bit and wait things out...
No comments:
Post a Comment